Serum β2-microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of disease severity?
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
05
2020
accepted:
14
02
2021
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
β2-microglobulin (β2-m), a 11.8 kDa protein, pairs non-covalently with the α3 domain of the major histocompatibility class (MHC) I α-chain and is essential for the conformation of the MHC class I protein complex. Shed β2-m is measurable in circulation, and various disorders are accompanied by increases in β2-m levels, including several viral infections. Therefore, we explored whether β2-m levels could also be elevated in Coronavirus disease 2019 (Covid-19) and whether they predict disease severity. Serum β2-m levels were measured in a cohort of 34 patients infected with SARS-CoV-2 on admission to a tertiary care hospital in Riyadh, Saudi Arabia, as well as in an approximately age-sex matched group of 34 uninfected controls. Mean β2-m level was 3.25±1.68 mg/l (reference range 0.8-2.2 mg/l) in patients (mean age 48.2±21.6) and 1.98±0.61 mg/l in controls (mean age 48.2±21.6). 17 patients (mean age 36.9± 18.0) with mean β2-m levels of 2.27±0.64 mg/l had mild disease by WHO severity categorization, 12 patients (mean age 53.3±18.1) with mean β2-m levels of 3.57±1.39 mg/l had moderate disease, and five patients (of whom 2 died; mean age 74.4±13.8) with mean β2-m levels of 5.85±1.85 mg/l had severe disease (P < = 0.001, by ANOVA test for linear trend). In multivariate ordinal regression β2-m levels were the only significant predictor of disease severity. Our findings suggest that higher β2-m levels could be an early indicator of severity of disease and predict outcome of Covid-19. As the main limitations of the study are a single-center study, sample size and ethnicity, these results need confirmation in larger cohorts outside the Arabian Peninsula in order to delineate the value of β2-m measurements. The role of β2-m in the etiology and pathogenesis of severe Covid-19 remains to be elucidated.
Identifiants
pubmed: 33647017
doi: 10.1371/journal.pone.0247758
pii: PONE-D-20-14213
pmc: PMC7920360
doi:
Substances chimiques
Biomarkers
0
beta 2-Microglobulin
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0247758Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Public Health. 2020 May;110(5):669-676
pubmed: 32267748
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Blood Purif. 2020 Dec 15;:1-11
pubmed: 33321496
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Front Immunol. 2019 May 29;10:1158
pubmed: 31191533
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Clin Virol. 2020 Aug;129:104449
pubmed: 32504943
Proc Natl Acad Sci U S A. 1986 Jan;83(2):446-50
pubmed: 3455781
Immunobiology. 2020 Nov;225(6):152008
pubmed: 33130519
Neurology. 2021 Jan 12;96(2):e294-e300
pubmed: 33004602
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
J Am Soc Nephrol. 2006 Nov;17(11):3067-75
pubmed: 17021266
Lupus. 2012 Sep;21(10):1098-104
pubmed: 22577117
Cell Rep. 2018 Jun 19;23(12):3512-3524
pubmed: 29924995
Ann Neurol. 2020 Aug;88(2):423-427
pubmed: 32418288
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Int J Antimicrob Agents. 2020 Sep;56(3):106103
pubmed: 32712333
Scand J Immunol. 2002 Nov;56(5):518-21
pubmed: 12410802
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Cell Death Dis. 2018 Sep 25;9(10):1002
pubmed: 30254192
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Ageing Res Rev. 2013 Sep;12(4):1069-78
pubmed: 23660515
Nephron. 2020;144(5):213-221
pubmed: 32203970
Kidney Int. 1987 Nov;32(5):635-41
pubmed: 3323598
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Clin Exp Immunol. 1997 Jul;109(1):54-8
pubmed: 9218824
EClinicalMedicine. 2020 Jun 03;23:100404
pubmed: 32632416
J Virol. 2020 Mar 17;94(7):
pubmed: 31996437
Immunol Rev. 2011 Sep;243(1):191-205
pubmed: 21884177
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Immune Netw. 2019 Nov 14;19(6):e37
pubmed: 31921467
Cell Death Differ. 2010 Mar;17(3):381-97
pubmed: 20019744
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
J Clin Pathol. 1984 Oct;37(10):1140-3
pubmed: 6092437
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
Front Med (Lausanne). 2017 Jun 15;4:73
pubmed: 28664159
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
J Clin Invest. 1989 May;83(5):1753-7
pubmed: 2540222
Life Sci. 2020 Aug 1;254:117788
pubmed: 32475810
Clin Vaccine Immunol. 2008 Jul;15(7):1124-7
pubmed: 18448621
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Arch Intern Med. 1990 Jan;150(1):73-7
pubmed: 1967523
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
FASEB J. 2015 Jul;29(7):2780-8
pubmed: 25782992
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Chest. 2020 Jul;158(1):97-105
pubmed: 32304772
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
Obes Res Clin Pract. 2020 Jul - Aug;14(4):295-300
pubmed: 32660813
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
JCI Insight. 2020 Jul 9;5(13):
pubmed: 32501293